The government-approved procedure for state control over price premiums for vital drugs will allow the Federal Antimonopoly Service to conduct on-site and documentary inspections, based on the results of which response measures will be taken. This was reported to “RG” in the press service of the FAS.
We are talking, in particular, about checks of primary documents, on the basis of which the regions calculate the maximum amount of allowances.
“If, according to the results of inspections of regional executive authorities, it is revealed that the premiums are set at an overestimated level, the FAS Russia will issue instructions to reduce them,” the FAS noted.
The supervisory authority added that now the regulation of prices for drugs included in the list of vital and essential ones is carried out at two levels: federal (when the Ministry of Health and the Federal Antimonopoly Service register the maximum selling prices of manufacturers, which Roszdravnadzor controls the use of which) and regional (the subjects themselves calculate and establish the maximum sizes of wholesale and retail markups to the actual selling prices of manufacturers after their agreement with the Federal Antimonopoly Service). At the regional level, control is exercised by Roszdravnadzor and regional regulatory authorities.
Earlier, Prime Minister Mikhail Mishustin demanded to maintain a balance in the drug market so that prices for essential drugs remain affordable for citizens.